Blood Advances · 2020 · 31 citations · 30 references
MedicineNutritional SciencesPharmacologyHemostasisLipid BiochemistryMolecular PharmacologyAntithrombotic TherapyEssential Fatty AcidsPlatelet ActivationPlatelet FunctionPlatelet PhysiologyThrombosis PreventionCardiovascular Effects Of Essential Fatty AcidsEssential Fatty Acid SupplementationLipoxygenase PathwayOmega-6 Fatty Acid MetabolismOxidized Lipid ProductsPlatelet Aggregation InhibitionPlatelet Function ModulationPlatelet Inhibition
Arterial thrombosis is the underlying cause for a number of cardiovascular-related events. Although dietary supplementation that includes polyunsaturated fatty acids (PUFAs) has been proposed to elicit cardiovascular protection, a mechanism for antithrombotic protection has not been well established. The current study sought to investigate whether an omega-6 essential fatty acid, docosapentaenoic acid (DPAn-6), and its oxidized lipid metabolites (oxylipins) provide direct cardiovascular protection through inhibition of platelet reactivity. Human and mouse blood and isolated platelets were treated with DPAn-6 and its 12-lipoxygenase (12-LOX)-derived oxylipins, 11-hydroxy-docosapentaenoic acid and 14-hydroxy-docosapentaenoic acid, to assess their ability to inhibit platelet activation. Pharmacological and genetic approaches were used to elucidate a role for DPA and its oxylipins in preventing platelet activation. DPAn-6 was found to be significantly increased in platelets following fatty acid supplementation, and it potently inhibited platelet activation through its 12-LOX-derived oxylipins. The inhibitory effects were selectively reversed through inhibition of the nuclear receptor peroxisome proliferator activator receptor-α (PPARα). PPARα binding was confirmed using a PPARα transcription reporter assay, as well as PPARα-/- mice. These approaches confirmed that selectivity of platelet inhibition was due to effects of DPA oxylipins acting through PPARα. Mice administered DPAn-6 or its oxylipins exhibited reduced thrombus formation following vessel injury, which was prevented in PPARα-/- mice. Hence, the current study demonstrates that DPAn-6 and its oxylipins potently and effectively inhibit platelet activation and thrombosis following a vascular injury. Platelet function is regulated, in part, through an oxylipin-induced PPARα-dependent manner, suggesting that targeting PPARα may represent an alternative strategy to treat thrombotic-related diseases.
30
Steven A. Kliewer, Scott S. Sundseth, Stacey A. Jones et al. · Proceedings of the National Academy of Sciences · 1997 · 2.2K citations · Full text
Lucy M. Browning, Celia G. Walker, Adrian Mander et al. · American Journal of Clinical Nutrition · 2012 · 314 citations · Full text
Effects of Icosapent Ethyl on Total Ischemic Events
Deepak L. Bhatt, Philippe Gabríel Steg, Michael Miller et al. · Journal of the American College of Cardiology · 2019 · 256 citations · Full text